Immunovia AB (publ) (IMMNOV.ST)
Develops blood tests that detect pancreatic cancer early through protein and antibody analysis
0.18-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-63.6%
The outlook
IMMNOV.ST trades near its 52-week lows and well below both its 50- and 200-day moving averages, signaling a weak near-term trend. Analyst coverage shows an average price target roughly 136% above the current price, though sentiment leans bearish overall. The stock sits at the lower end of its yearly range, reflecting depressed valuations against analyst expectations.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range5% of the way from its 52-week low to high
Price targetAvg target +136% vs current price
Market cap
$119.9M
52-wk high
0.75
52-wk low
0.15
50-day avg
0.19
200-day avg
0.22
Trailing P/E
—